Roughly a year and a half after Tocagen (NASDAQ: TOCA) named Marty Duvall as CEO, the San Diego biotech said it has signed a deal that gives Beijing-based ApolloBio an exclusive license to its gene therapy treatment for a deadly type of brain cancer. Under terms of the deal, ApolloBio agreed to make a $16 […]
Original Article: Tocagen Reaches Exclusive Deal in China for Brain Cancer Therapy